VIRIDIAN THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.9 USD | -0.07% |
|
-9.74% | -36.18% |
| May. 09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
| May. 09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to the Viridian Therape...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
13.9
USD
Average target price
36.5
USD
Spread / Average Target
+162.59%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -36.18% | 887M | |
| +17.96% | 44.96B | |
| +48.77% | 41.85B | |
| +1.17% | 42.65B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Transcript : Viridian Therapeutics, Inc., Q2 2022 Earnings Call, Aug 15, 2022